.jpg?format=webp&width=780)
The study assessed the use of once-weekly semaglutide in adults with type 2 diabetes in real-world clinical practice in France. The primary endpoint was the change in HbA1c levels from baseline to the end of the study, with secondary endpoints including changes in body weight and waist circumference, and the proportion of patients achieving HbA1c targets. The study found that semaglutide was effective in improving glycemic control and reducing body weight in this population, with no new safety concerns identified. The results support the use of semaglutide in a real-world setting in France.
Like
Save
Share